4//SEC Filing
Ratliff John D 4
Accession 0001127602-19-005984
CIK 0000920148other
Filed
Feb 13, 7:00 PM ET
Accepted
Feb 14, 4:08 PM ET
Size
14.8 KB
Accession
0001127602-19-005984
Insider Transaction Report
Form 4
Ratliff John D
CEO, Covance Drug Development
Transactions
- Exercise/Conversion
Common Stock
2019-02-12+1,463→ 16,255 total - Tax Payment
Common Stock
2019-02-12$146.59/sh−654$95,870→ 15,601 total - Exercise/Conversion
Restricted Stock Unit
2019-02-12−1,463→ 16,911 total→ Common Stock (1,463 underlying) - Award
Restricted Stock Unit
2019-02-12+5,300→ 22,211 total→ Common Stock (5,300 underlying) - Award
Non-qualified Stock Options
2019-02-12+21,800→ 21,800 totalExercise: $146.59From: 2020-02-12Exp: 2029-02-11→ Common Stock (21,800 underlying)
Holdings
- 40(indirect: By Trust)
Common Stock
- 80(indirect: By Trust)
Common Stock
Footnotes (8)
- [F1]Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
- [F2]Stock withholding to satisfy tax withholding obligations.
- [F3]The reporting person is not a trustee of the irrevocable trust and disclaims beneficial ownership of the shares.
- [F4]The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on 2/12/19.
- [F5]This number reflects the aggregate number of Restricted Stock Units held by the reporting person.
- [F6]The Restricted Stock Units vest in three equal annual installments beginning on 2/12/2020.
- [F7]Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.
- [F8]The option vests in three equal installments beginning on the date reflected in this column.
Documents
Issuer
LABORATORY CORP OF AMERICA HOLDINGS
CIK 0000920148
Entity typeother
Related Parties
1- filerCIK 0001575951
Filing Metadata
- Form type
- 4
- Filed
- Feb 13, 7:00 PM ET
- Accepted
- Feb 14, 4:08 PM ET
- Size
- 14.8 KB